The global PD-L1 biomarker testing market is expected to reach US$ 9.7 billion by 2028, growing at a CAGR of 16.5% during the forecast period 2023-2028. This growth can be attributed to the increasing prevalence of cancer and the growing importance of personalized medicine in cancer treatment. PD-L1 biomarker testing is a type of diagnostic test used to identify the presence of PD-L1 protein in cancer cells, which can help in the selection of appropriate immunotherapy treatments.
Ph123
Cm88 - Nhà Cái Uy Tín
Chaitanya
Va Auto Motor Inc
Fly88
888new
J88 Nhà Cái Cá Cược
Abrahamsen Mccollum
Cjjf Santa Monica, Ca
Bowles Heating And Cooling